Anagenics Ltd (AN1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anagenics Ltd (AN1) has a cash flow conversion efficiency ratio of -0.286x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-649.97K ≈ $-459.90K USD) by net assets (AU$2.27 Million ≈ $1.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Anagenics Ltd's balance sheet to measure how much of total assets are equity-financed.
Anagenics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Anagenics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AN1 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Anagenics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anagenics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianci International, Inc. Common Stock
NASDAQ:CIIT
|
-0.002x |
|
Samchai Steel Industries Public Company Limited
BK:SAM
|
-0.061x |
|
Conferize A/S
CO:CONFRZ
|
-0.072x |
|
Bold Ventures Inc
V:BOL
|
-0.065x |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
-0.038x |
|
Astrotech Corp
NASDAQ:ASTC
|
-0.228x |
|
Tantech Holdings Ltd
NASDAQ:TANH
|
-0.022x |
|
Polar Capital Global Financials Trust plc
LSE:PCFT
|
0.010x |
Annual Cash Flow Conversion Efficiency for Anagenics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Anagenics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Anagenics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.83 Million ≈ $1.29 Million |
AU$-1.58 Million ≈ $-1.12 Million |
-0.863x | -34.52% |
| 2024-06-30 | AU$2.71 Million ≈ $1.92 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.641x | -220.49% |
| 2023-06-30 | AU$8.90 Million ≈ $6.29 Million |
AU$-1.78 Million ≈ $-1.26 Million |
-0.200x | +34.30% |
| 2022-06-30 | AU$8.29 Million ≈ $5.87 Million |
AU$-2.53 Million ≈ $-1.79 Million |
-0.305x | +22.73% |
| 2021-06-30 | AU$10.43 Million ≈ $7.38 Million |
AU$-4.11 Million ≈ $-2.91 Million |
-0.394x | +3.61% |
| 2020-06-30 | AU$9.81 Million ≈ $6.94 Million |
AU$-4.01 Million ≈ $-2.84 Million |
-0.409x | +59.63% |
| 2019-06-30 | AU$5.86 Million ≈ $4.14 Million |
AU$-5.93 Million ≈ $-4.20 Million |
-1.013x | +57.27% |
| 2018-06-30 | AU$1.86 Million ≈ $1.31 Million |
AU$-4.40 Million ≈ $-3.11 Million |
-2.371x | -156.64% |
| 2017-06-30 | AU$4.40 Million ≈ $3.11 Million |
AU$-4.06 Million ≈ $-2.87 Million |
-0.924x | -70.01% |
| 2016-06-30 | AU$4.69 Million ≈ $3.32 Million |
AU$-2.55 Million ≈ $-1.80 Million |
-0.543x | +34.34% |
| 2015-06-30 | AU$3.77 Million ≈ $2.67 Million |
AU$-3.12 Million ≈ $-2.21 Million |
-0.828x | -109.28% |
| 2014-06-30 | AU$5.66 Million ≈ $4.01 Million |
AU$-2.24 Million ≈ $-1.58 Million |
-0.395x | -44.41% |
| 2013-06-30 | AU$5.31 Million ≈ $3.75 Million |
AU$-1.45 Million ≈ $-1.03 Million |
-0.274x | +67.46% |
| 2012-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.841x | +26.36% |
| 2011-06-30 | AU$2.04 Million ≈ $1.44 Million |
AU$-2.33 Million ≈ $-1.65 Million |
-1.143x | -178.85% |
| 2010-06-30 | AU$2.85 Million ≈ $2.02 Million |
AU$-1.17 Million ≈ $-826.04K |
-0.410x | +72.49% |
| 2009-06-30 | AU$738.65K ≈ $522.64K |
AU$-1.10 Million ≈ $-778.46K |
-1.489x | +41.77% |
| 2008-06-30 | AU$615.63K ≈ $435.60K |
AU$-1.57 Million ≈ $-1.11 Million |
-2.558x | -35.58% |
| 2007-06-30 | AU$1.53 Million ≈ $1.08 Million |
AU$-2.89 Million ≈ $-2.05 Million |
-1.886x | -364.75% |
| 2006-06-30 | AU$5.59 Million ≈ $3.95 Million |
AU$-2.27 Million ≈ $-1.61 Million |
-0.406x | -- |
About Anagenics Ltd
Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pac… Read more